Indrayani Biotech Ltd (INDRANIB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Indrayani Biotech Ltd on NSE and BSE, with an AI summary of each filing.
Revised outcome of the Rights Issue Committee held on November 03, 2026
Rights Issue · 04 Nov 2026, 1:18 am
Indrayani Biotech Approves Allotment of 83.64 Lakh Rights Equity Shares Indrayani Biotech's Rights Issue Committee on 3rd Nov'26 approved the allotment of 83,64,036 equity shares (face value ₹10 each) at an issue price of ₹15 per share (including ₹5 premium). The allotment comprises 75,03,333 fully paid-up shares and 8,60,703 partly paid-up shares (₹3.75 paid on application, including ₹1.25 premium). Consequently, the company's paid-up equity capital increased from ₹45.54 cr (4,55,36,256 fully paid shares) to ₹53.25 cr (5,30,39,589 fully paid shares and 8,60,703 partly paid-up shares at ₹2.50 face value paid-up).
Outcome of the Rights Issue Committee Meeting held on November 03, 2026
Rights Issue · 03 Nov 2026, 11:16 pm
Indrayani Biotech Approves Allotment of 83.64 Lakh Rights Equity Shares Indrayani Biotech approved the allotment of 83,64,036 partly paid-up rights equity shares at ₹15 per share (₹5 premium) on 3rd Nov'26, following BSE approval of the basis of allotment on 2nd Nov'26. The company received application money of ₹3.75 per share (₹2.50 face value, ₹1.25 premium). Consequently, the paid-up equity share capital expanded from ₹45.54 cr (4,55,36,256 fully paid shares) to ₹53.04 cr, comprising 5,30,39,589 fully paid shares of ₹10 each and 8,60,703 partly paid shares (₹2.50 paid-up).
Indrayani Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve 1. Notice of the 34th Annual ....
Intimation · 03 Nov 2026, 8:11 pm
Appointment of Ms. Nattery Srinivasan Poornima, Company Secretary in Practice, as the Secretarial Auditor of the Company.
Change in Auditor · 02 Nov 2026, 11:43 pm
Indrayani Biotech Appoints Secretarial Auditor and Accepts CS Resignation Indrayani Biotech Limited’s Board approved the appointment of Ms. Nattery Srinivasan Poornima as Secretarial Auditor for FY25-26, effective 2nd Nov'26, filling the casual vacancy caused by Mr. K. Ravichandran’s resignation on 6th Aug'26. Additionally, the Board accepted the resignation of Company Secretary and Compliance Officer Mr. C.S. Shanmuga Sundar due to personal reasons, which took effect at the close of business hours on 2nd Nov'26 following the completion of his 45-day notice period.
Resignation of Mr. C. S. Shanmuga Sundar as a Company Secretary and Compliance Officer of the Company.
Change in Management · 02 Nov 2026, 11:35 pm
Indrayani Biotech Approves Secretarial Auditor Appointment and CS Resignation Indrayani Biotech Limited’s Board approved key corporate actions on 2nd Nov'26. The company appointed Ms. Nattery Srinivasan Poornima, Practicing Company Secretary, as Secretarial Auditor for FY26 to fill the casual vacancy resulting from Mr. K. Ravichandran’s resignation on 6th Aug'26. Additionally, the Board accepted the resignation of Mr. C.S. Shanmuga Sundar as Company Secretary and Compliance Officer, effective close of business on 2nd Nov'26 following the completion of his 45-day notice period tendered on 17th Sep'26 due to personal and health reasons.
Outcome of the Board Meeting held on November 02, 2026.
Others (Uncategorized) · 02 Nov 2026, 11:31 pm
Indrayani Biotech Board Approves Auditor Appointment and Key Managerial Resignation Indrayani Biotech Limited's Board of Directors approved key corporate changes on 2nd Nov'26. The board appointed Ms. Nattery Srinivasan Poornima as Secretarial Auditor for FY25-26 to fill the casual vacancy created by the resignation of Mr. K. Ravichandran on 6th Aug'26. Additionally, the company accepted the resignation of Mr. C.S. Shanmuga Sundar from the role of Company Secretary and Compliance Officer due to personal reasons, effective from the close of business hours on 2nd Nov'26 following the completion of his 45-day notice period.
Update on Income Tax Recovery Proceeding.
Others (Uncategorized) · 21 Oct 2026, 11:37 pm
Indrayani Biotech Responds to Income Tax Recovery Letter Indrayani Biotech has filed a formal response against an Income Tax recovery notice regarding outstanding demands across AY12 to AY14. For AY14, the company requested the deletion of a ₹98.09 lakh demand, citing that ITAT previously set aside the underlying order on 2nd Nov'20. For AY12 and AY13, involving a combined demand of ₹18.46 lakh related to excise duty disallowances, it sought to keep recovery in abeyance pending first-appeal adjudication. The company expects no immediate financial impact, maintaining strong legal grounds.
Resignation of Mr. K.S. Vaidyanathan, Independent Director from Board of Directors of Indrayani Biotech Limited.
Change in Management · 13 Oct 2026, 10:57 pm
Indrayani Biotech Independent Director Resigns Indrayani Biotech Limited announced the resignation of Independent Director Mr. K.S. Vaidyanathan (DIN: 01122393), effective close of business on 13th Oct'26. The resignation, submitted via letter on 12th Oct'26 citing personal reasons due to reaching 65 years of age, was accepted by the Board of Directors on 13th Oct'26. The company confirmed there are no other material reasons for his departure, and he holds no board or committee positions in other listed entities.
Unaudited Standalone & Consolidated Financial Results for quarter ended June 30, 2026 along with Limited Review Report.
Financial Result · 07 Oct 2026, 11:38 pm
Indrayani Biotech Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakhs) ■ Revenue: 3,771 (+29.6% YoY | -0.2% QoQ) ■ EBITDA: 147 (-32.7% YoY | -33.7% QoQ) ■ EBITDA Margin (%): 3.9 (-360 bps YoY | -197 bps QoQ) ■ PAT: 26.2 (+156.1% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.06 (+200.0% YoY | Loss to Profit QoQ)
Unaudited Standalone & Consolidated Financial Results For The Quarter Ended 30th June 2026 Along With Limited Review Report.
Outcome · 07 Oct 2026, 11:28 pm
Indrayani Biotech Limited has informed the Sale of Shares of Subsidiary Company under Regulation 30 of SEBI LODR 2015
Others (Uncategorized) · 01 Oct 2026, 5:28 am
Indrayani Biotech Divests 1.83% Stake in Subsidiary Dindigul Farm Product via Open Market Indrayani Biotech completed the sale of a 1.83% stake in its subsidiary, Dindigul Farm Product Limited, via the open market on 30th Sep'26. Following the divestment, Indrayani Biotech retains a 27.05% shareholding in the entity. Dindigul Farm Product holds a paid-up capital of Rs. 24.43 cr and reported a turnover of Rs. 90.04 cr, contributing 65.33% to the parent company's revenues during the previous financial year. The transaction does not involve related-party interests.
Indrayani Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/10/2026 ,inter alia, to consider and approve 1. Unaudited Financial Results ....
Intimation · 07 Oct 2026, 5:30 am
Indrayani Biotech Schedules Board Meeting for Q1 Results and Committee Reconstitution Indrayani Biotech Limited has informed BSE that a meeting of its Board of Directors is scheduled for 7th Oct'26. The Board will consider and approve the standalone and consolidated unaudited financial results of the company for the quarter ended 30th Jun'26, along with the Limited Review Report from the Statutory Auditors. Additionally, the Board will deliberate on a proposal for the reconstitution of various Board Committees.
Letter of Offer for Rights Issue
Rights Issue · 10 Sept 2026, 1:59 am
Outcome of the Rights Issue Committee held 09th September,2026.
Rights Issue · 10 Sept 2026, 1:52 am
Indrayani Biotech Revises Partly Paid-up Rights Issue Schedule The Rights Issue Committee of Indrayani Biotech Limited approved a revised schedule for its partly paid-up Rights Issue on 9th Sep'26. The issue is now scheduled to open on 15th Sep'26 and close on 14th Oct'26, following prior postponements. Additionally, the last date for on-market renunciation has been set to 8th Oct'26. The revised Letter of Offer and associated issue documents have been made available on the BSE and the company's website.
Appointment of Mr. C.S. Shanmuga Sundar, as a company secretary and compliance officer of the company. W.e.f. 09th September, 2026.
Change in Management · 10 Sept 2026, 12:35 am
Indrayani Biotech Appoints Shanmuga Sundar as Company Secretary and Compliance Officer Indrayani Biotech Limited announced that its Board of Directors approved the appointment of Mr. C.S. Shanmuga Sundar as Company Secretary & Compliance Officer, effective 9th Sep'26. He succeeds Ms. Ramya Ravi, who resigned effective 3rd Jun'26. Mr. Shanmuga Sundar, an Associate Company Secretary since 27th Apr'19, previously served at Peiner Smag Machinery, overseeing secretarial, compliance, and corporate governance functions. The company confirmed that he is not related to any directors on the Board.
Resignation of Mr. K. Ravichandran as the Secretarial Auditor of the Company.
Change in Auditor · 08 Sept 2026, 12:12 am
Indrayani Biotech Announces Resignation of Secretarial Auditor Indrayani Biotech Limited disclosed that Mr. K. Ravichandran has resigned from his position as Secretarial Auditor of the company, effective 6th Aug'26, citing personal reasons. The Audit Committee and Board of Directors will consider and approve the appointment of a new Secretarial Auditor in due course to fill the casual vacancy, with subsequent intimations to follow.
Approval received for AGM Extension (FY 2025-26)
Annual General Meeting · 07 Sept 2026, 11:16 pm
Audited financial results for quarter and year ended March 31, 2026 along with report of statutory auditors.
Others (Uncategorized) · 19 Aug 2026, 9:48 pm
Indrayani Biotech Posts FY26 Profit; Auditor Issues Qualified Opinion Indrayani Biotech reported a consolidated net profit of ₹216.03 lakhs for FY26, a significant turnaround from a loss of ₹610.75 lakhs in FY25. For Q4 FY26, net profit was ₹97.60 lakhs versus a loss of ₹852.59 lakhs YoY. However, the statutory auditor issued a qualified opinion on the FY26 results. Qualifications include the inability to verify loans, assets, and receivables; non-compliance with IND AS for two subsidiaries; and a lack of balance confirmations for trade creditors at a subsidiary, representing 41% of its total liabilities.
Audited Standalone & consolidated financial results for the quarter and year ended 31st March 2026 along with report of statutory auditors.
Outcome · 17 Aug 2026, 10:26 pm
Indrayani Biotech Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 7,278 (+43.9% YoY | +107.9% QoQ) ■ EBITDA: 500 (Loss to Profit YoY | +79.3% QoQ) ■ EBITDA Margin (%): 6.9 (Loss to Profit YoY | -109 bps QoQ) ■ PAT: 109 (Loss to Profit YoY | +845.1% QoQ) ■ EPS (INR): 0.24 (Loss to Profit YoY | +700.0% QoQ)
Audited Standalone & Consolidated financial results for the quarter and year ended March 31, 2026 along with auditors report.
Financial Result · 17 Aug 2026, 10:22 pm
Indrayani Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 ,inter alia, to consider and approve Indrayani Biotech Ltd has ....
Intimation · 17 Aug 2026, 5:30 am
Indrayani Biotech Board to Approve Q4 & FY26 Results on 17 Aug'26 Indrayani Biotech (BSE: 526445) announced a Board of Directors meeting scheduled for 17 Aug'26. The primary agenda is to consider and approve the audited financial results for the quarter and financial year ended 31 Mar'26. The board will also take on record the auditor's report for the financial year. This meeting is a key event for the release of the company's full-year performance data.
Company has received GST revocation order
Others (Uncategorized) · 16 Jul 2026, 9:42 pm
Indrayani Biotech's GST Registration Revocation Order Received Indrayani Biotech received an order on 15 Jul'26 from the GST Department revoking the cancellation of its GST registration. The initial cancellation, effective from 28 Apr'26, was due to the non-filing of returns. The revocation is also effective retroactively from 28 Apr'26. The company stated there is no financial or operational impact from this event. This resolves the litigation initiated on 09 Jun'26.
Company has received IT Order
Others (Uncategorized) · 15 Jul 2026, 10:49 pm
Indrayani Biotech Receives Favorable Ruling in Income Tax Dispute On 14-Jul-26, the Income Tax Appellate Tribunal quashed an order from the First Appellate Authority regarding an Assessment Order dated 26-Mar-25. The Tribunal has restored the case to the First Appellate Authority for fresh adjudication. The company's tax litigation, initiated on 09-Mar-26, is now disclosed as culminated following this development. This ruling positively resolves a key tax dispute for Indrayani Biotech, pending the outcome of the new adjudication process.
Company has received IT order
Others (Uncategorized) · 15 Jul 2026, 10:46 pm
Indrayani Biotech Receives Favorable Ruling in Tax Litigation Case Indrayani Biotech's tax litigation dispute, initiated on Mar 09, '26, has seen a significant development. The Income Tax Appellate Tribunal, in an order dated Jul 14, '26, quashed the prior order from the First Appellate Authority. The case, which challenges an assessment order dated Mar 26, '25, has now been restored to the file of the First Appellate Authority for fresh adjudication. The company's disclosure indicates the ongoing litigation status has now culminated, pending the new hearing.
Compliance Certificate Under Reg 74(5) of SEBI (Depositories and Participants) Regulation, 2018, for the quarter ended on 30th June, 2026.
Others (Uncategorized) · 06 Jul 2026, 9:15 pm
Indrayani Biotech Files Compliance Certificate for Quarter Ended Jun'26 Indrayani Biotech (Scrip Code: 526445) filed a compliance certificate under SEBI Regulation 74(5) for the quarter ended 30 Jun'26. The certificate, issued by Registrar and Transfer Agent MUFG Intime India, confirms the timely processing of dematerialization requests. It verifies that securities received for dematerialization were processed, and depository names were substituted in the register of members within the prescribed timelines. This is a routine compliance filing indicating proper handling of share dematerialization and reconciliation with depositories.